Biodegradable injectable implants containing glycolic acid
First Claim
1. A biodegradable, injectable implant comprising glycolic acid monomer and particles comprised of a polymer comprising lactic acid repeats units, wherein the particles have a diameter of from about 20 μ
- to about 120 μ and
are suspended in a pharmaceutically accentable carrier, and the glycolic acid monomer is present in a concentration of from about 1.8 mcg to about 18.2 mcg glycolic acid monomer per 100 ml of the pharmaceutically acceptable carrier.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention is directed to the field of medical implants, and more specifically to biodegradable injectable implants and their methods of manufacture and use. The injectable implants disclosed herein comprise glycolic acid and bio-compatible/bio-absorbable polymeric particles containing a polymer of lactic acid. The particles are small enough to be injected through a needle but large enough to avoid engulfment by macrophages. The injectables of this invention may be in a pre-activated solid form or an activated form (e.g., injectable suspension or emulsion).
201 Citations
69 Claims
-
1. A biodegradable, injectable implant comprising glycolic acid monomer and particles comprised of a polymer comprising lactic acid repeats units, wherein the particles have a diameter of from about 20 μ
- to about 120 μ and
are suspended in a pharmaceutically accentable carrier, and the glycolic acid monomer is present in a concentration of from about 1.8 mcg to about 18.2 mcg glycolic acid monomer per 100 ml of the pharmaceutically acceptable carrier. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)
- to about 120 μ and
-
39. A biodegradable, injectable implant comprising glycolic acid monomer and particles comprised of polylactic acid, wherein the particles have a mean diameter of from about 40μ
- to about 80μ and
are suspended in a pharmaceutically acceptable carrier, and the glycolic acid monomer is present in a concentration of from about 1.8 mcg to about 18.2 mcg glycolic acid monomer per 100 ml of the pharmaceutically acceptable carrier. - View Dependent Claims (40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)
- to about 80μ and
-
63. A biodegradable, injectable implant comprising:
- a) glycolic acid monomer, wherein the glycolic acid monomer is present in a concentration of from about 12 mcg to about 13 mcg glycolic acid monomer per 100 ml of suspension;
b) particles of polylactic acid, wherein the particles have a mean diameter of from about 40μ
to about 80μ
;
c) a gelling agent;
d) a surfactant;
e) a cryoprotecting agent; and
f) a buffering agent, wherein the implant comprises an aqueous suspension of particles of the polylacticacid. - View Dependent Claims (64, 65, 66, 67, 68, 69)
- a) glycolic acid monomer, wherein the glycolic acid monomer is present in a concentration of from about 12 mcg to about 13 mcg glycolic acid monomer per 100 ml of suspension;
Specification